UC San Francisco researchers are launching CANOPY, a global study that will follow as many as 3,000 people who plan to take psychedelics at home, at organized retreats, and in other everyday settings. The goal is to measure how these drugs affect mood, well-being, and other psychological outcomes outside the controlled environment of a research lab, where most of what is known about psychedelics has come from.
Unlike a traditional clinical trial, the study will not provide participants with psychedelics or decide what they take. Instead, it enrolls people who are already planning to use them, and the work will be conducted mostly remotely. The substances covered include psilocybin, LSD, ayahuasca, ibogaine, MDMA, and ketamine. Participants will complete standardized assessments before their experience and for up to six months afterward. Some who can travel to UCSF will also undergo brain imaging and EEG and provide blood and saliva samples, and all participants may use wearable devices to collect physiological data outside the lab.
CANOPY is one of three UCSF psychedelic projects funded by the Advanced Research Projects Agency for Health (ARPA-H), a federal agency within the U.S. Department of Health and Human Services. The three awards total up to $8.5 million. CANOPY itself received up to $1.4 million and is led by Robin Carhart-Harris, PhD, a UCSF professor of neurology. A second ARPA-H-funded project, co-led by Jennifer Mitchell, PhD, will examine how mindset and environment influence psychedelic effects. A third, co-led by Mitchell and Lorenzo Pasquini, PhD, will study psychedelics in older adults with low well-being and biomarkers associated with preclinical Alzheimer's disease.
Researchers hope the data will help explain why psychedelic experiences can produce very different outcomes from person to person, and separate the effects of the drug from individual, biological, psychological, and environmental factors linked to beneficial or harmful results over time. The project is also designed as a platform for more targeted studies, with the aim of informing future clinical trials and helping scientists assess risks and benefits when psychedelics are used outside controlled settings. Researchers are recruiting adults who already plan to use a psychedelic and are willing to complete assessments. UCSF does not supply the substances or direct anyone to obtain them.